Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Mise à jour : Il y a 4 ans
Référence : NCT01421524

Femme et Homme

Extrait

The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.


Critère d'inclusion

  • Multiple myeloma ,Lymphoma, Large B-Cell, Diffuse ,Pleiotropic Pathway Modifier ,Glioblastoma ,LYMPHOMA ,Primary central nervous system lymphoma


Liens